Description of drug: Thiophosphamidum (Thiophosphamidum)

THIOPHOSPHAMPIDE (Thiophosphamidum).

N, N ', N "-Tri (ethylene) -triamide of thiophosphoric acid, or N, N', N" -Triethylenimine thiophosphamide.

Synonyms: TioTEF, Deltespamine, Oncotepal, Thiofosyl, Thiotepa, Thio-TEPA, Tespamin, Tifosyl, TSPA.

White crystalline (lyophilized) powder or plates. Easily soluble in water. Aqueous solutions are unstable and can not be sterilized, since they are easily hydrolyzed.

Thiophosphamide exerts a cytostatic effect and inhibits the development of proliferating, including malignant, tissue. In the mechanism of action of these compounds, an important role is played by the disruption of the exchange of nucleic acids and the blockade of mitotic cell division.

Applied thiophosphamide in ovarian cancer (with advanced forms, for preoperative treatment, in the postoperative period), breast cancer (with relapses and metastases, inoperable tumors, for pleurisy, in the postoperative period) and some other tumors (mesothelioma, retinoblastoma, urinary cancer Bubble).

The use of thiophosphamide contributes to a decrease in the number of relapses and metastases after radical mastectomy, and in the complex treatment of breast cancer, increases the percentage of disease-free flow of the process.

Possible use of thiophosphamide in chronic lymphocytic leukemia and chronic myeloid leukemia (with leukemia), lymphogranulomatosis, reticulosarcoma, lymphosarcomatosis.

The drug is available in hermetically sealed vials containing 0.01 or 0.02 g (10 or 20 mg) of the drug in the form of a powder or tablets. Solutions are prepared immediately before use: inject 5 or 10 ml of sterile water for injection into the vial from the syringe.

Thiophosphamide can be administered intramuscularly, intravenously, intraarterially and in the cavity (intrapleural and intraperitoneal). Direct injection into the tumor is also possible.

The doses and timing of treatment should be strictly individual, depending on the nature of the disease, the general condition of the patient, the effectiveness of treatment and the tolerability of the drug.

Patients with a body weight of 60 to 70 kg are given thiophosphamide, usually in a single dose of 0.015 g (15 mg); Patients with a stable hematopoietic system can enter at the beginning of the course of treatment 20 mg; Patients with a small body weight and with a propensity for leukopenia prescribe 10 mg. The drug is administered every other day (3 times a week). For the course of treatment 0.15 - 0.2 g (150 - 200 mg).

During the treatment, the blood is systematically examined. Treatment is stopped with a decrease in the number of white blood cells to 3 x 10 9 / l and platelets to 100 x 10 / L. Hematologic examinations are carried out within 2 to 3 weeks after the end of the course of treatment, as the reduction in the number of leukocytes can continue after the drug is discontinued.

At incomplete effect from the first course of treatment or at relapses, spend a course of treatment repeatedly with an interval of 1, 5 - 3 months; On the course apply 0.15 - 0.2 g of the drug (under the control of hematological studies).